Literature DB >> 15612452

Molecular mechanisms of increased glucose production: identifying potential therapeutic targets.

Joseph Proietto1, Sofianos Andrikopoulos.   

Abstract

Many patients with type 2 diabetes go on to require insulin therapy to achieve adequate control. A need remains to develop new classes of oral hypoglycemic agents to complement those already in use. A useful target is the inappropriately elevated endogenous glucose production present in patients with type 2 diabetes. This review discusses mechanisms of increased glucose production and possible strategies and targets for its suppression. Several approaches are being investigated, including inhibitors of glycogenolysis and gluconeogenesis, inhibitors of stimulatory hormones or their receptors, metabolic modulators, and agents that alter gene expression. There is a high probability that one of these approaches will soon result in a safe and effective inhibitor of glucose production.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15612452     DOI: 10.1136/jim-52-06-33

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  3 in total

1.  T-cell protein tyrosine phosphatase attenuates STAT3 and insulin signaling in the liver to regulate gluconeogenesis.

Authors:  Atsushi Fukushima; Kim Loh; Sandra Galic; Barbara Fam; Ben Shields; Florian Wiede; Michel L Tremblay; Matthew J Watt; Sofianos Andrikopoulos; Tony Tiganis
Journal:  Diabetes       Date:  2010-05-18       Impact factor: 9.461

2.  The role of hepatic, renal and intestinal gluconeogenic enzymes in glucose homeostasis of juvenile rainbow trout.

Authors:  Séverine Kirchner; Stéphane Panserat; Pauline L Lim; Sadasivam Kaushik; Ronaldo P Ferraris
Journal:  J Comp Physiol B       Date:  2008-01-08       Impact factor: 2.200

3.  Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis.

Authors:  Roberto Conti; Edoardo Mannucci; Pompeo Pessotto; Emanuela Tassoni; Paolo Carminati; Fabio Giannessi; Arduino Arduini
Journal:  Diabetes       Date:  2011-02       Impact factor: 9.461

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.